9 October 2024
The focus of the industry is living organisms, and the highly monitored standards make it a unique concern for business leaders. These aspects make the sector an ideal place to foster innovation. They have produced major breakthroughs in agricultural yields, biofuels, and life-saving pharmaceuticals.
When you think of strategies to generate revenue biotech startups have a variety of options. Most choose a technology partnership or an asset-creation-and-out-licensing strategy. Technology partnering can generate more revenue and lower financial risk, whereas outlicensing and asset creation strategies are able to yield much greater returns. An increasing number of biotechs that are in research phase operate a hybrid model that combines both strategies.
Those who opt for the approach of developing based on products will be successful commercially if they can get their pipeline to the right stage and also attract a significant pharmaceutical partner or an investor with deep pockets. This can be www.genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ a costly proposition but managing opportunistic approaches to leverage outside assets with the right scientific decisions about homegrown projects is key.
In addition, the “platform” model offers an alternative way to earn revenue. It is a less expensive option than the product-oriented development but it comes with substantial risk. In this model biotechs create and own their own platform technology, before teaming with big pharma to create a portfolio of drug discovery initiatives that target specific diseases (i.e. disease of x in biology). This is the model Advinus Therapeutics and a few others have followed.